Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-2426 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1a: Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-2426 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 week, whichever occurs first. |
| Phase 1b: Monotherapy Dose Expansion | EXPERIMENTAL | Participants will be enrolled in different indication-specific cohorts. Participants will receive GS-2426 monotherapy at the recommended dose until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol, or up to a maximum of 105 weeks, whichever occurs first. |
| Name | Type | Description |
|---|---|---|
| GS-2426 | DRUG | Administered Orally |
Key Inclusion Criteria: * Participants 18 years of age or older (≥ 19 years old for participants in South Korea). * Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatm...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
GS-2426 is an investigational small molecule being developed by Gilead Sciences, Inc. for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development and is a biomarker-selected therapy, meaning trial enrollment is guided by a specific biomarker. GS-2426 has not been approved by the FDA.
GS-2426 is being studied as a treatment for advanced solid tumors in adults 18 years and older. It is an investigational agent in Phase 1 testing and is not approved for any indication. The ongoing trial enrolls participants with advanced solid tumors and uses biomarker selection to identify eligible patients.
GS-2426 is being developed by Gilead Sciences, Inc., which trades on the Nasdaq under the ticker GILD. Gilead is the sponsor of the Phase 1 clinical program evaluating GS-2426 in advanced solid tumors. The drug remains investigational and has not received regulatory approval.
GS-2426 is in Phase 1 clinical development. The single ongoing trial is a Phase 1 study in participants with advanced solid tumors and is currently recruiting. GS-2426 is investigational and has not been approved by the FDA for any use.
GS-2426 is being evaluated in one Phase 1 trial, NCT07601243, titled Study of GS-2426 in Participants With Advanced Solid Tumors. The trial is recruiting, has an estimated enrollment of 174 participants, and is being conducted in the United States and Spain. It enrolls adults 18 years and older of all sexes.